Harnessing the therapeutic potential of host antiviral restriction factors that target HIV

References

• Bushman FD, Malani N, Fernandes J et al. Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog. 5(5), e1000437 (2009).
   PubMed Web of Science ®Google Scholar
• Malim MH, Bieniasz PD. HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med. 2(5), a006940 (2012).
   PubMed Web of Science ®Google Scholar
• Pillai SK, Abdel-Mohsen M, Guatelli J et al.; Swiss HIV Cohort Study. Role of retroviral restriction factors in the interferon-a-mediated suppression of HIV-1 in vivo. Proc. Natl Acad. Sci. USA 109(8), 3035–3040 (2012).
   PubMed Web of Science ®Google Scholar
• Hultquist JF, Harris RS. Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virol. 4(6), 605 (2009).
   PubMedGoogle Scholar
• Nathans R, Cao H, Sharova N et al. Small-molecule inhibition of HIV-1 Vif. Nat. Biotechnol. 26(10), 1187–1192 (2008).
   PubMedGoogle Scholar
• Cen S, Peng ZG, Li XY et al. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J. Biol. Chem. 285(22), 16546–16552 (2010).
   PubMedGoogle Scholar
• Berkhout B, de Ronde A. APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS 18(13), 1861–1863 (2004).
   PubMedGoogle Scholar
• Sadler HA, Stenglein MD, Harris RS, Mansky LM. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J. Virol. 84(14), 7396–7404 (2010).
   PubMedGoogle Scholar
• Li M, Shandilya SM, Carpenter MA et al. First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem. Biol. 7(3), 506–517 (2012).
   PubMedGoogle Scholar
• Kim EY, Bhattacharya T, Kunstman K et al. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J. Virol. 84(19), 10402–10405 (2010).
   PubMedGoogle Scholar
• Fourati S, Malet I, Lambert S et al. E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure. AIDS 26(13), 1619–1624 (2012).
   PubMedGoogle Scholar
• Jern P, Russell RA, Pathak VK, Coffin JM. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog. 5(4), e1000367 (2009).
   Google Scholar
• Montal M. Vpu matchmakers as a therapeutic strategy for HIV infection. PLoS Pathog. 5(5), e1000246 (2009).
   Google Scholar
• Zhang Q, Liu Z, Mi Z et al. High-throughput assay to identify inhibitors of Vpu-mediated down-regulation of cell surface BST-2. Antiviral Res. 91(3), 321–329 (2011).
   PubMed Web of Science ®Google Scholar
• Khoury G, Ewart G, Luscombe C, Miller M, Wilkinson J. Antiviral efficacy of the novel compound BIT225 against HIV‑1 release from human macrophages. Antimicrob. Agents Chemother. 54(2), 835–845 (2010).
   PubMedGoogle Scholar
• Kuhl BD, Cheng V, Donahue DA et al. The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonism. PLoS ONE 6(11), e27660 (2011).
   Google Scholar
• Price AJ, Marzetta F, Lammers M et al. Active site remodeling switches HIV specificity of antiretroviral TRIMCyp. Nat. Struct. Mol. Biol. 16(10), 1036–1042 (2009).
   PubMedGoogle Scholar
• Caines ME, Bichel K, Price AJ et al. Diverse HIV viruses are targeted by a conformationally dynamic antiviral. Nat. Struct. Mol. Biol. 19(4), 411–416 (2012).
   PubMedGoogle Scholar
• Neagu MR, Ziegler P, Pertel T et al. Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J. Clin. Invest. 119(10), 3035–3047 (2009).
   PubMed Web of Science ®Google Scholar
• Shi J, Zhou J, Shah VB, et al. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J. Virol. 85(1), 542–549 (2011).
   PubMed Web of Science ®Google Scholar
• Christ F, Voet A, Marchand A et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat. Chem. Biol. 6(6), 442–448 (2010).
   PubMed Web of Science ®Google Scholar
• Albin JS, Harris RS. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev. Mol. Med. 12, e4 (2010).
   PubMedGoogle Scholar
• Brass AL, Huang IC, Benita Y et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139(7), 1243–1254 (2009).
   PubMed Web of Science ®Google Scholar
• Lu J, Pan Q, Rong L, He W, Liu SL, Liang C. The IFITM proteins inhibit HIV-1 infection. J. Virol. 85(5), 2126–2137 (2011).
   PubMed Web of Science ®Google Scholar
• Rider TH, Zook CE, Boettcher TL, Wick ST, Pancoast JS, Zusman BD. Broad-spectrum antiviral therapeutics. PLoS ONE 6(7), e22572 (2011).
   PubMed Web of Science ®Google Scholar